Fujian Haixi Pharmaceuticals Co (HKSE:02637) Construction In Progress: HK$41.8 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02637 Fujian Haixi Pharmaceuticals Co Ltd HKSE:02637
23 GF Score
Price HK$204.80
! 2 Warning Signs
View Full Analysis

What is Fujian Haixi Pharmaceuticals Co Construction In Progress?

Fujian Haixi Pharmaceuticals Co HKSE:02637 +3.28% 23 Construction In Progress is HK$41.8 Mil as of Dec. 2025. GuruFocus rates HKSE:02637 with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Fujian Haixi Pharmaceuticals Co's quarterly construction in progress increased from Dec. 2023 (HK$103.7 Mil) to Dec. 2024 (HK$294.3 Mil) but then declined from Dec. 2024 (HK$294.3 Mil) to Dec. 2025 (HK$41.8 Mil).

Fujian Haixi Pharmaceuticals Co's annual construction in progress increased from Dec. 2023 (HK$103.7 Mil) to Dec. 2024 (HK$294.3 Mil) but then declined from Dec. 2024 (HK$294.3 Mil) to Dec. 2025 (HK$41.8 Mil).

Fujian Haixi Pharmaceuticals Co Construction In Progress Historical Data

* Premium members only.

The historical data trend for Fujian Haixi Pharmaceuticals Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fujian Haixi Pharmaceuticals Co Construction In Progress Chart

Fujian Haixi Pharmaceuticals Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Construction In Progress
32.43 103.70 294.33 41.84

Fujian Haixi Pharmaceuticals Co Semi-Annual Data
Dec22 Dec23 Dec24 Dec25
Construction In Progress 32.43 103.70 294.33 41.84
HKSE:02637
23GF Score
Fujian Haixi Pharmaceuticals Co Ltd HKSE:02637
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fujian Haixi Pharmaceuticals Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of HK$41.8 Mil mean?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a Construction In Progress of HK$41.8 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors.
Is Fujian Haixi Pharmaceuticals Co's Construction In Progress too high?
Fujian Haixi Pharmaceuticals Co's current Construction In Progress is HK$41.8 Mil. Overall, Fujian Haixi Pharmaceuticals Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Fujian Haixi Pharmaceuticals Co's Construction In Progress compare to ZTS?
Fujian Haixi Pharmaceuticals Co's Construction In Progress of HK$41.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. Fujian Haixi Pharmaceuticals Co's current Construction In Progress is HK$41.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Haixi Pharmaceuticals Co stock overvalued right now?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a current Construction In Progress of HK$41.8 Mil. The current Construction In Progress is HK$41.8 Mil. Fujian Haixi Pharmaceuticals Co's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Fujian Haixi Pharmaceuticals Co (HKSE:02637), the current Construction In Progress is HK$41.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Fujian Haixi Pharmaceuticals Co Business Description

Address No. 177 Jinda Road, Floor 3rd & 4th, Block B, Jianxin Town, Cangshan District,Fujian Province, Fuzhou, CHN, 350028
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
23GF Score

Get the complete analysis for HKSE:02637

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$204.80
Price